academic article

• Generic oncology drugs: are they all safe?.  The Lancet. Oncology.  17:e493-e501. 2016
• Regulatory and clinical considerations for biosimilar oncology drugs..  The Lancet. Oncology.  15:e594-e605. 2014
• A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR)..  Seminars in thrombosis and hemostasis.  38:783-796. 2012